Inclusion Criteria:

        Subject must meet all the following applicable inclusion criteria to participate in this
        study:

          -  Written informed consent and HIPAA authorization for release of personal health
             information prior to registration. NOTE: HIPAA authorization may be included in the
             informed consent or obtained separately.

          -  Age ≥ 18 years at the time of consent.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of = 2

          -  Able to comply with the study protocol, in the investigator's judgment.

          -  Histologically documented, locally advanced (T4b, any N; or any T, N 2-3) or
             metastatic urothelial carcinoma (mUC) (M1, Stage IV) (also termed TCC or UCC of the
             urinary tract; including renal pelvis, ureters, urinary bladder, and urethra) Patients
             with mixed histologies are required to have a dominant transitional cell pattern.
             Locally advanced bladder cancer must be inoperable on the basis of involvement of
             pelvic sidewall or adjacent viscera (clinical Stage T4b) or bulky nodal metastasis
             (N2-N3).

          -  Measurable disease, as defined by RECIST v1.1

          -  Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens (metastatic
             specimens preferable but if not available primary tumor specimens that are at least
             muscle-invasive are acceptable) in paraffin blocks (blocks preferred) or at least 15
             unstained slides. Subjects without adequate archival tumor tissue or for whom a biopsy
             is not considered possible may be considered for enrollment on a case by case basis
             after discussion with the sponsor-investigator.

          -  No prior chemotherapy for inoperable locally advanced or mUC. For patients who
             received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial
             carcinoma, a treatment-free interval > 12 months between the last treatment
             administration and the date of recurrence is required in order to be considered
             treatment naive in the metastatic setting.

          -  Cisplatin-ineligible as defined by at least one of the following:

               -  Calculated creatinine clearance ≥ 30 (Cockroft-Gault)

               -  ECOG performance status of 2 or greater

               -  CTCAE v4 Grade ≥ 2 audiometric hearing loss

          -  Demonstrate adequate organ function. All screening labs to be obtained within 28 days
             prior to registration:

               -  Hematological:

                    -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9/L

                    -  Hemoglobin (Hgb) ≥ 9 g/dL

                    -  Platelets ≥ 100 x 10^9/L

               -  Renal:

                  • Calculated creatinine clearance ≥ 30 mL/min (Cockroft-Gault)

               -  Hepatic:

                    -  Bilirubin ≤ 1.5 × upper limit of normal (ULN) (except subjects with Gilbert
                       Syndrome, who can have total bilirubin < 3.0 mg/dL)

                    -  Aspartate aminotransferase (AST) ≤ 3 × ULN

                    -  Alanine aminotransferase (ALT) ≤ 3 × ULN

          -  Women of childbearing potential must have a negative serum or urine pregnancy.

          -  Women of childbearing potential (WOCBP) must use appropriate method(s) of
             contraception as stated for the timeline below. Male subjects are not required to use
             contraception.

        NOTE: Women of childbearing potential is defined as any female who has experienced menarche
        and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy)
        or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in
        a woman over 45 in the absence of other biological or physiological causes. In addition,
        women under the age of 62 must have a documented serum follicle stimulating hormone (FSH)
        level less than 40 mIU/mL.

        NOTE: Women of childbearing potential (WOCBP) receiving nivolumab will be instructed to
        adhere to contraception for a period of 5 months after the last dose of investigational
        product.

        Exclusion Criteria:

        Subjects meeting any of the criteria below may not participate in the study:

          -  Active infection requiring systemic therapy.

          -  Pregnant or breastfeeding

          -  Any serious or uncontrolled medical disorder that, in the opinion of the site
             investigator, may increase the risk associated with study participation or study drug
             administration, impair the ability of the subject to receive protocol therapy, or
             interfere with the interpretation of study results.

          -  Prior malignancy active within the previous 3 years except for locally curable cancers
             that have been apparently cured.

          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only
             requiring hormone replacement, psoriasis not requiring systemic treatment, or
             conditions not expected to recur in the absence of an external trigger are permitted
             to enroll.

          -  Subjects with a condition requiring systemic treatment with either corticosteroids (>
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration. Inhaled or topical steroids and adrenal replacement
             doses > 10 mg daily prednisone equivalents are permitted in the absence of active
             autoimmune disease.

          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or
             any other antibody or drug specifically targeting T-cell co-stimulation or immune
             checkpoint pathways.

          -  Grade ≥ 2 neuropathy (NCI CTCAE version 4).

          -  Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus
             ribonucleic acid (RNA) or hepatitis C antibody (HCV antibody) indicating acute or
             chronic infection.

          -  Known history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS).

          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis.

          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease
             (Class III or greater), myocardial infarction within 3 months prior to randomization,
             unstable arrhythmias, or unstable angina.

          -  Known left ventricular ejection fraction (LVEF) < 40% Patients with known coronary
             artery disease, congestive heart failure not meeting the above criteria, or LVEF
             40%-50% must be on a stable medical regimen that is optimized in the opinion of the
             treating physician, in consultation with a cardiologist if appropriate.

          -  Solid organ or tissue transplant including stem cell transplant